Compare · DRS vs TMO
DRS vs TMO
Side-by-side comparison of Leonardo DRS Inc. (DRS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRS and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $248.91B, about 26.7x DRS ($9.33B).
- Over the past year, DRS is down 10.4% and TMO is up 29.7% - TMO leads by 40.2 points.
- DRS has been more active in the news (10 items in the past 4 weeks vs 7 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 13 for DRS).
- Company
- Leonardo DRS Inc.
- Thermo Fisher Scientific Inc
- Price
- $35.47+1.56%
- $696.50+3.45%
- Market cap
- $9.33B
- $248.91B
- 1M return
- -4.41%
- +7.40%
- 1Y return
- -10.44%
- +29.72%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 10
- 7
- Recent ratings
- 13
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest DRS
- Leonardo DRS Expands Federal Access to Mission-Critical Technologies Through NASA SEWP VI
- Leonardo DRS Awarded JIATF-401 IDIQ Contract to Accelerate Delivery of Tactical Expeditionary Sensing Capabilities for Critical Counter UAS Mission
- Leonardo DRS Selected to Advance Next-Generation Uncooled Thermal Infrared Sensing for U.S. Army DUTCH Initiative
- Leonardo DRS Strengthens Dismounted Soldier Modernization With $63 Million FWS-I Production Order
- Leonardo DRS CEO John Baylouny Receives AUSA John W. Dixon Award
- Leonardo DRS Launches cxMHR, a Fully Digital C-Band Radar for Integrated Air and Missile Defense
- Leonardo DRS Completes Training and Delivery of INOD Block III Thermal Weapon Sights for the Australian Army
- Leonardo DRS Establishes UK Subsidiary and Launches Local Capabilities for its Tactical Radars including Full Manufacturing
- Director Townsend Frances F converted options into 1,006 shares, increasing direct ownership by 3% to 36,894 units (SEC Form 4)
- Leonardo DRS Schedules Third Quarter 2026 Earnings Conference Call for October 29, 2026
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)